Table 1

Patient and pathologic characteristics

CharacteristicAll
N (%)
CRS1
N (%)
CRS2
N (%)
CRS3
N (%)
P value
Cases (n)108241866
Median age (range) (years)65.0 (36–85)63.5 (43–79)67.0 (45–85)65.0 (36–85)0.723
FIGO stage0.678
 IIIC91 (84.3)19 (79.2)16 (88.9)56 (84.8)
 IV17 (15.7)5 (20.8)2 (11.1)10 (15.2)
Median ascites before NACT (range) (ml*)2250 (200–10400)2000 (250–10400)2250 (200–8000)2500 (400–7000)0.864
Median CA125 before NACT (range) (UI/ml†)593.0 (33–10195)766.5 (42–10195)508.5 (152–9769)593.0 (33–7038)0.894
Median CA125 before IDS (range) (UI/ml‡)11 (0–34)10 (5–27)16 (4–34)11 (0–31)0.213
NACT regimen0.159
 Carboplatin-based90 (83.3)23 (95.8)15 (83.3)52 (78.8)
 Carbotaxol+bevacizumab18 (16.7)1 (4.2)3 (16.7)14 (21.2)
NACT cycles (n)0.120
 3–484 (77.8)21 (87.5)11 (61.1)52 (78.8)
 >524 (22.2)3 (12.5)7 (38.9)14 (21.2)
BRCA status‡0.829
 Wild-type23 (53.5)4 (44.4)5 (55.6)14 (56.0)
 Mutated20 (46.5)5 (55.6)4 (44.4)11 (44.0)
  • *Information available for 58 patients.

  • †Information available for 98 patients.

  • ‡Information available for 105 patients.

  • §Information available for 43 patients.

  • BRCA, BReast CAncer gene; CRS, chemotherapy response score; FIGO, International Federation of Gynecology and Obstetrics; IDS, interval debulking surgery; NACT, neoadjuvant chemotherapy.